Avalia Immunotherapies collapses, owes $1m to Callaghan Innovation

Avalia Immunotherapies collapses, owes $1m to Callaghan Innovation
Dr Shivali Gulab, CEO of Avalia Immunotherapies. (Image: Avalia)
Riley Kennedy
Liquidators have been appointed to a biotech outfit that helped produce a covid-19 vaccine after it failed to raise cash to help further its other project.Founded in 2015, Avalia Immunotherapies was a preclinical-stage biotech company attempting to develop a fully synthetic vaccine and immunotherapy platform. Its lead programme was targeting a functional cure for chronic Hepatitis B.After it couldn’t raise further funding for clinical development, Baker Tilly Staples Rodway’s Tony Maginness and Jared Booth were appointed liquid...

More Finance

Payments NZ could play key role in open banking standards
Finance

Payments NZ could play key role in open banking standards

A draft decision proposes an 18-month approval, rather than the five years requested.

Singapore becomes hot spot for M&A bankers hunting Asia deals
Finance

Singapore becomes hot spot for M&A bankers hunting Asia deals

The island is a magnet for parties interested in mergers and acquisitions.

Bloomberg 28 Jun 2024
Medicine working but business confidence continues to fall
Finance

Medicine working but business confidence continues to fall

Confidence in retail and construction rose, while other sectors were more downbeat.

Tom Raynel 27 Jun 2024
Shareholders association opposes Geneva Finance delisting
Finance

Shareholders association opposes Geneva Finance delisting

Company says it will exceed USX governance rules.

Jem Traylen 26 Jun 2024